Related references
Note: Only part of the references are listed.Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2013)
Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions
Stacey D. Finley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Chandrajit P. Raut et al.
PLOS ONE (2012)
Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
Jeffrey A. Meyerhardt et al.
PLOS ONE (2012)
Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab
G. C. Jayson et al.
EUROPEAN JOURNAL OF CANCER (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
Dan G. Duda et al.
ONCOLOGIST (2010)
Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
Lei Xu et al.
CANCER RESEARCH (2009)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
Christian Stockmann et al.
NATURE (2008)
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer
AM Jubb et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
